Oral probiotics inhibit upper respiratory tract infections

 

 

oraticx oral probiotics

 

A study showing that oral probiotic inhibits major pathogens of upper respiratory tract infection was introduced in an international journal.

Oral probiotics company Orapharm conducted in vitro experiments on the action of oral probiotics on major pathogens of upper respiratory tract infection from March 2020 to January 2021.

The upper respiratory tract of the bronchial tubes corresponds to the mouth, nose, and throat of the body, and upper respiratory infections refer to respiratory diseases that have invaded the upper respiratory tract due to colds, pharyngitis, laryngitis, and acute bronchitis.

There is no special treatment for bacterial upper respiratory tract infections other than antibiotics, and if a biofilm is formed, it is difficult to treat them with antibiotics.

The antibacterial effect of Orapharm oral probiotics, oraCMU and oraCMS1, on major pathogens of upper respiratory tract infection and the inhibition and removal of biofilm formation of pathogens were tested.

1. Effect of inhibiting biofilm formation

2. Biofilm removal effect


This study is meaningful in that it has suggested new possibilities for the prevention and treatment of upper respiratory tract infections through probiotics.


The research paper was published in the SCI-level international journal Microorganisms Vol. 9 No. 6 in 2021.​



To read more in Korean: visit Health Chosun